Mass Spectrometry-Based Assay for the Molecular Diagnosis of Glioma: Concomitant Detection of Chromosome 1p/19q Codeletion, and IDH1, IDH2, and TERT Mutation Status

Oncotarget - United States
doi 10.18632/oncotarget.19103
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas

American Journal of Neuroradiology
MedicineNuclear MedicineNeurologyImagingRadiology
2019English

Optical Analysis of Glioma: Fourier-Transform Infrared Spectroscopy Reveals the IDH1 Mutation Status.

Clinical Cancer Research
Cancer ResearchOncology
2017English

CDKN2C Homozygous Loss Identifies a Distinct Subtype of TP53/RB1-wildtype Leiomyosarcoma With Frequent CIC Genomic Alterations and 1p/19q-Codeletion

2020English

Assessment of 1p/19q Deletion by Flourescence Insitu Hybridization (FISH) in Glioma Patients From Andhrapradesh

Molecular Cytogenetics
BiochemistryMolecular MedicineGeneticsMolecular Biology
2014English

IDH1 Mutation Diminishes Aggressive Phenotype in Glioma Stem Cells

International Journal of Oncology
Cancer ResearchOncology
2017English

IDH1 R132H Mutation Regulates Glioma Chemosensitivity Through Nrf2 Pathway

Oncotarget
Oncology
2017English

IDH1/2 Mutation Status Combined With Ki-67 Labeling Index Defines Distinct Prognostic Groups in Glioma

Oncotarget
Oncology
2015English

Molecular and Mass Spectrometry Detection and Identification of Causative Agents of Bloodstream Infections

2016English

Imaging Correlates for the 2016 Update on WHO Classification of Grade II/III Gliomas: Implications for IDH, 1p/19q and ATRX Status

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy